CUL2

Cullin-2 · Q13617 · CUL2 on Sugi Atlas →

0 patent compounds predicted against CUL2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CUL2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study PHASE3COMPLETED
Multi-site Adaptive Trials for COVID-19 PHASE3COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders. PHASE1/PHASE2RECRUITING
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease EARLY_PHASE1RECRUITING
ADAPT: Efficacy of a Dietary Supplement During and After Exercise nanCOMPLETED
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC) nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Assessment of Residual VHL Function in Tumors - Can it Predict the Patients' Individual Course of Disease? nanUNKNOWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Drivers of Hypoxia-induced Angiogenesis in Tumor Development nanUNKNOWN
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders nanRECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients nanRECRUITING
Characterization of Angelman Syndrome nanCOMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease nanCOMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Ohio Colorectal Cancer Prevention Initiative nanCOMPLETED
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) nanRECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Cleidocranial Dysplasia (CCD): From Genotype to Phenotype and Considerations for Care nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a CUL2 binder may also engage these)

ProteinNameSimilarity
Q9D4H8 1.000 Q9D4H8 →
Q5RCF3 1.000 Q5RCF3 →
Q24311 1.000 Q24311 →
A4IHP4 0.998 A4IHP4 →
Q6GPF3 0.997 Q6GPF3 →
Q9JLV5 0.996 Q9JLV5 →
Q6DE95 0.996 Q6DE95 →
Q17390 0.996 Q17390 →
CUL3 Cullin-3 0.995 landscape →
O60999 0.994 O60999 →
Q94AH6 0.993 Q94AH6 →
Q23639 0.992 Q23639 →
B5DF89 0.991 B5DF89 →
Q5ZC88 0.990 Q5ZC88 →
P0CH31 0.990 P0CH31 →
Q9ZVH4 0.988 Q9ZVH4 →
Q54NZ5 0.988 Q54NZ5 →
Q9C9L0 0.987 Q9C9L0 →
O13790 0.987 O13790 →
Q17391 0.985 Q17391 →
Q17389 0.984 Q17389 →
Q9SRZ0 0.982 Q9SRZ0 →
Q7Q068 0.982 Q7Q068 →
Q8LGH4 0.981 Q8LGH4 →
Q17D30 0.981 Q17D30 →
Q6DK91 0.980 Q6DK91 →
Q6P2K6 0.978 Q6P2K6 →
Q9I8E6 0.977 Q9I8E6 →
Q7Z392 0.977 Q7Z392 →
Q9QZE5 0.977 Q9QZE5 →